Evidence map›Paper›PMID 33392504›Full record

ArticleNeuro-oncology advances

Data-driven prioritization and preclinical evaluation of therapeutic targets in glioblastoma.

Cyrillo G Brahm, U Kulsoom Abdul, Megan Houweling, Myra E van Linde, Tonny Lagerweij, Henk M W Verheul, Bart A Westerman, Annemiek M E Walenkamp, Rudolf S N Fehrmann

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Radio-sensitizing effect of MEK inhibition in glioblastoma in vitro and in vivo.Journal of cancer research and clinical oncology · 2023
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Cyrillo G BrahmDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
U Kulsoom AbdulDepartment of Neurosurgery, Cancer Center Amsterdam, Brain Tumor Center Amsterdam, Amsterdam University Medical Centers, Location VUmc, Amsterdam, The Netherlands.
Megan HouwelingDepartment of Neurosurgery, Cancer Center Amsterdam, Brain Tumor Center Amsterdam, Amsterdam University Medical Centers, Location VUmc, Amsterdam, The Netherlands.
Myra E van LindeDepartment of Medical Oncology, Cancer Center Amsterdam, Brain Tumor Center Amsterdam, Amsterdam University Medical Centers, Location VUmc, Amsterdam, The Netherlands.
Tonny LagerweijDepartment of Neurosurgery, Cancer Center Amsterdam, Brain Tumor Center Amsterdam, Amsterdam University Medical Centers, Location VUmc, Amsterdam, The Netherlands.
Henk M W VerheulDepartment of Medical Oncology, Cancer Center Amsterdam, Brain Tumor Center Amsterdam, Amsterdam University Medical Centers, Location VUmc, Amsterdam, The Netherlands.
Bart A WestermanDepartment of Neurosurgery, Cancer Center Amsterdam, Brain Tumor Center Amsterdam, Amsterdam University Medical Centers, Location VUmc, Amsterdam, The Netherlands.
Annemiek M E WalenkampDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Rudolf S N FehrmannDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Amsterdam University Medical Centers · NLUniversity Medical Center Groningen · NLRadboud University Medical Center · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with glioblastoma (GBM) have a dismal prognosis, and there is an unmet need for new therapeutic options. This study aims to identify new therapeutic targets in GBM.

methodsmRNA expression data of patient-derived GBM (

resultsWe identified 712 significantly upregulated genes in GBM compared to normal brain tissue, of which 27 have a known interaction with antineoplastic agents. Seventeen of the 27 genes, including

conclusionsThe MAPK9 inhibitor RGB-286638 showed promising in vitro results. Furthermore, in vivo target engagement studies and combination therapies with this compound warrant further exploration.

Indexed as

glioblastomaMAPK9RRM2therapeutic targetsXIAP

Identifiers

PMID33392504
PMCPMC7764503
OpenAlexW3097843799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.